Advertisement

Topics

Companies Related to "Chronic AsthmaGlobal Manufacturers Marketed Phase Drugs Landscape 2017" [Most Relevant Company Matches] RSS

20:20 EST 20th February 2019 | BioPortfolio

Here are the most relevant search results for "Chronic AsthmaGlobal Manufacturers Marketed Phase Drugs Landscape 2017" found in our extensive corporate database of over 50,000 company records.

Showing "Chronic AsthmaGlobal Manufacturers Marketed Phase Drugs Landscape 2017" Companies 1–25 of 4,300+

Relevant

Intec Pharma Ltd.

Intec Pharma Ltd. is a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. The Company's Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and s...


Salubris

Shenzhen Salubris Pharmaceuticals Co., Ltd. (Salubris) is a publicly traded, fully integrated pharmaceutical company [002294:CH]. Founded in 1998, Salubris has grown to achieve sales of >$750M USD in 2017. Salubris is headquartered in Shenzhen, China, and has over 3,800 employees working across R&D, regulatory, marketing and sales. Its marketed products in...

Landscape Structures

Since 1971, Landscape Structures Inc. has been the leading commercial playground equipment manufacturer in the world. The only major playground equipment company that is employee-owned, Landscape Structures encourages outdoor play that develops healthy kids and a sustainable world by creating innovative products that are environmentally responsible. The company's mission from day one has been to e...


Biofrontera AG

Biofrontera AG is a biopharmaceutical company specializing in the development of drugs for the treatment of dermatological and inflammatory diseases. The Company has three product candidates in clinical development for four different clinical indications. The most advanced products are BF-200 ALA (Phase IIb/III) for actinic keratosis and condyloma; and BF-derm 1 (Phase II) for chronic, antihistami...

PolyMedix

PolyMedix is the leader in developing biomimetics - novel small molecule, oligomer and polymer protein-mimetic drugs for membrane protein and protein:protein targets. PolyMedix has a proven computational technology platform which was used to develop its first program: a line of unique anti-infective drugs for which bacterial resistance is highly unlikely to develop. Proteins are the machinery of ...

DeuteRx, LLC

DeuteRx has pioneered ‘deuterium-enabled chiral switching’ (DECS), a revolutionary approach to improve racemic (a mixture of two mirror-image compounds or enantiomers) small molecule marketed drugs and drug candidates intended for patients across multiple therapeutic indications. The development of the single, preferred enantiomer from the parent...

Synthetic Turf Council

Based in Atlanta, the Synthetic Turf Council was founded in 2003 to promote the industry and to assist buyers and end users with the selection, use and maintenance of synthetic turf systems in sports field, golf, municipal parks, airports, landscape and residential applications. The organization is also a resource for current, credible, and independent research on the safety and environmental imp...

DeuteRx LLC

DeuteRx is pioneering ‘deuterium-enabled chiral switching’ (DECS), a revolutionary approach to improve racemic (a mixture of two mirror-image compounds or enantiomers) small molecule marketed drugs and drug candidates intended for patients across multiple therapeutic indications. Numerous drugs are still developed and marketed as racemic mixtures...

Topigen Pharmaceuticals Inc.

TOPIGEN is developing several new classes of drugs and is actively progressing two drug candidates in Phase II trials for COPD and asthma. These drugs are uniquely focused on inhibiting multiple inflammation targets underlying the chronic pulmonary diseases. TOPIGEN also has a number of discovery research programs focused on the identification of novel compounds for the treatment of COPD and aller...

EPIX Pharmaceuticals

EPIX Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products through the use of proprietary technology to better diagnose, treat and manage patients. The company has five internally-discovered therapeutic and imaging drug candidates currently in clinical trials targeting conditions such as depression, Alzheimer's disease, ...

Fibrotech Therapeutics

Fibrotech is an Australian biopharmaceutical company developing a new class of drugs to prevent a massive health burden associated with fibrosis (tissue scarring). The Company develops novel anti-fibrotic drug candidates for the treatment of the fibrosis prevalent in such chronic conditions as chronic kidney disease, chronic heart failure, pulmonary fibros...

FortuneRock (China) Ltd.

FortuneRock (China) Ltd., a privately held biotechnology and biopharmaceutical company registered in Beijing. Along with its 3 wholly owned subsidiaries, Tianjin SinoBiotech Ltd., SinoBiotech (Tianjin) Ltd. and Beijing Bio-Fortune Ltd., the group is focused on the discovery, development, and commercialization of novel, patent-protected gene-based recombina...

Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, inflammatory disease and sexual dysfunction. The Company's lead drug candidate, Piclidenoson, is scheduled to enter Phase III trials in 2...

American Society of Landscape Architects (ASLA)

Founded in 1899, the American Society of Landscape Architects (ASLA) is the national professional association for landscape architects, representing more than 15,000 members in 49 professional chapters and 76 student chapters. The Society's mission is to lead, to educate, and to participate in the careful stewardship, wise planning, and artful design of ou...

Syngenix Limited

SynGenix Limited SynGenix has developed technologies that effectively target drugs and drug discovery tools to the anatomical and cellular sites of origin of disease processes. SynGenix can delivery probes such as antisense in vivo for > drug target validation and systems for targeting small drugs and macromolecules to the site of disease. The core platform technologies have been demonstrated by...

Aestus Therapeutics, Inc.

Aestus Therapeutics, Inc. is a translational medicine company focused on serious neurological diseases. Capitalizing on genomic data analysis to discover novel links between these diseases and well-studied biological pathways, Aestus identifies drug candidates already in clinical Phase 1 or later. By developing these drugs in novel disease areas such as ch...

Gene Network Sciences

Gene Network Sciences (GNS) is a privately held biosimulation company with offices in Ithaca, New York, and Cambridge, Massachusetts. Founded in 2000, GNS creates data-driven compound simulation models that help pharmaceutical companies improve the quality of their drug candidates. Leading the company's multi-disciplinary approach are scientists specializing in molecular biology, computer science,...

Inverseon, Inc.

Inverseon's product development programs target significant unmet medical needs and major market opportunities in chronic pulmonary diseases such as asthma, COPD and pulmonary hypertension. Inverseon was founded based on the original work of Prof. Richard Bond of the University of Houston. Professor Bond termed the effects “Paradoxical Pharmacologyâ...

Lupin Pharmaceuticals, Inc

Lupin is one of the world's largest manufacturers of drugs that combat tuberculosis,bacterial infections,and cardiovascular disease.Our portfolio of drugs, manufactured in global-scale USFDA and UKMCA approved plants,also includes NSAIDS,Cox2 inhibitors and herbal-based phytomedicines.

FortuneRock (China) Co., Ltd.

FortuneRock (China) Co., Ltd., a biotechnology and biopharmaceutical company registered in Beijing. Along with its 3 subsidiaries, Tianjin SinoBiotech Ltd., SinoBiotech (Tianjin) Ltd. and Beijing Bio-Fortune Ltd., the group is focused on the discovery, development, and commercialization of novel, patent-protected gene-based recombinant protein drugs with h...

Aestus Therapeutics and Prosidion Ltd.

Aestus Therapeutics, Inc. is a translational medicine company focused on serious neurological diseases. Capitalizing on genomic data analysis to discover novel links between these diseases and well-studied biological pathways, Aestus identifies drug candidates in clinical Phase I or later. By developing these drugs in novel disease areas such as chronic pa...

Prestwick Pharmaceuticals, Inc.

Prestwick Pharmaceuticals, Inc, is a product-based, specialty pharmaceutical company engaged in the development and marketing of small molecule drugs for chronic diseases of the central nervous system (CNS). Following our founding in 2002, we rapidly acquired rights to a promising portfolio of small molecule drugs, all with unique attributes and targeting chronic CNS conditions not adequately serv...

Prosidion Ltd

(OSI) Prosidion is the diabetes and obesity business group within OSI Pharmaceuticals, Inc. (NASDAQ:OSIP) dedicated to the discovery and development of novel drugs for the treatment of type 2 diabetes and obesity. (OSI) Prosidion's lead compound PSN9301 is a Dipeptidyl Peptidase IV (DP-IV) inhibitor currently in Phase II clinical trials. PSN357, a glycogen phosphorylase inhibitor, is undergoing Ph...

bioRASI

bioRASI is a full service global CRO providing optimized pipeline development TM. This strategic initiative of the Russian Academy of Sciences conducts research throughout the Americas, Europe, and Asia, and is experienced in biologicals, medical devices, and small drugs, maintaining equal balance between Pilot, Phase I/BE, and Phase II/IV studies.

Vasogen

We are focused on the research and commercial development of technologies targeting the chronic inflammation underlying cardiovascular and neurological disease. The recently completed international 2,400-patient ACCLAIM trial assessed the impact of our Celacade™ technology on reducing the risk of mortality and morbidity in patients with advanced heart failure. Full results for the ACCLAIM study ...


More From BioPortfolio on "Chronic AsthmaGlobal Manufacturers Marketed Phase Drugs Landscape 2017"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks